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There are two main reasons for changing antiretroviral
therapy (ART) – firstly toxicity or intolerance, and secondly
failure of the current regimen. Other reasons include poor
adherence that may be improved with another regimen and
new data becoming available suggesting that a new drug or
regimen is superior to the existing regimen.
TOXICITY OR INTOLERANCE
Readers are referred to the SA HIV Clinicians Guidelines for
Paediatric ART (p. 18, this issue). 
When a patient exhibits intolerance to or toxicity from a single
drug it may be acceptable to just replace the offending drug
with another that does not have the same toxicity, e.g.
replacing AZT with d4T in the case of bone marrow toxicity
caused by AZT.  In rare instances a reduction in dosage may be
considered, but only where the new reduced dose will still
provide the necessary therapeutic range.
Where a severe toxic reaction such as lactic acidosis or
abacavir hypersensitivity reaction occurs, all ART should be
stopped until the patient recovers. Only then can one
cautiously restart ART. The offending agent should be
switched for one that does not have the same toxicity profile. 
FAILURE OF CURRENT REGIMEN
Ideally one should not change therapy based on a single viral 
load (VL) estimation or CD4 count. VL and CD4 may be falsely
affected by intercurrent infections or recent vaccinations.
Ideally, therefore, these investigations should be repeated
after 1 month before considering changing therapy.
Before any consideration is given to changing ART, a thorough
assessment of adherence issues should be made. As discussed
below, adherence is the most important factor in determining
the success of an ART regimen.7-9 Adherence issues should first
be resolved before changing therapy.
The US Public Health Service Guidelines10 lists three types of
failure of an antiretroviral regimen – virological, immuno-
logical or clinical failure (Table I). Children differ from adults in
their response to therapy. As mentioned above, this may be
changing with the advent of newer more potent drugs. In
addition, children may have a very good immunological and
clinical response to ART despite not having an undetectable
viral load. This leads to the following dilemma:
■ if they are changed too soon, there is a risk of using up all
available agents in a short space of time
■ if they are kept on the 'failing' regimen, there is a risk of
accumulating resistance mutations.
Most paediatric experts would not change the therapy if the
viral load is < 10 000 copies/ml and the CD4 count is normal
or increasing and the child is doing well clinically. This
approach, however, does lead to the accumulation of
resistance mutations,11 which means that when one eventually
changes regimens it is no longer a simple case of moving from
the prescribed first-line to the second-line regimen.  Therefore
it is imperative that a paediatric ART expert be consulted
whenever a change in therapy is contemplated.
Isolated viral load 'blips', e.g. single levels of 50 - 1 000
copies/ml, are not usually associated with subsequent
virological failure.12,13 In children with low CD4 counts an
opportunistic infection may still occur before the immune
system has recovered and is not an indication to change ART.
An important principle in treating patients with HIV is that the first regimen is your best chance for success. So get it right the
first time. Historically children have always lagged behind adults in their (virological) response to antiretrovirals (ARVs).1-3
However, with improvements in knowledge about pharmacokinetics, adherence and newer more potent and tolerable drugs in
children, response to therapy in children is now approximating that in adults.4-6 Nevertheless, it is inevitable that over time, for
a variety of reasons, a significant number of patients will need to move to a second-line regimen. For this reason, it is important
that we have an approach to changing therapy.
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Please note: The recommendations given in this article are
merely a guide. There is no substitute for expert advice when
changing ART. Please consult the SA HIV Clinicians Society or
the author for a list of local and overseas experts who would
be willing to assist you.
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Similarly, immune reconstitution inflammatory syndrome
(IRIS) is not an indication to change ART.
CHANGING THERAPY
DIFFERENT SCENARIOS WHEN CHANGING ART
There are three main scenarios encountered when changing
ART for drug failure.
■ Early failure of a first regimen – there is unlikely to be
much cross-resistance, and a simple choice of a different
regimen is usually adequate.
■ Intermediate failure of a first regimen – some cross-
resistance may be present. Genotyping may be helpful in
ascertaining the degree of cross-resistance.
■ Extensive prior treatment – extensive drug resistance is
likely.
INITIAL ASSESSMENT
Initial assessment is important in determining the cause of
failure, as frequently the same issues will be a barrier to the
success of a subsequent regimen.
Assessing adherence
Adherence is the most important factor in determining the
success of an ART regimen.7-9 Virological failure often follows
poor adherence. It is therefore logical that if poor adherence is
the reason for failure of a regimen, one should not change
therapy until the adherence issues have been resolved. Since
the first regimen is often the best tolerated regimen,
subsequent regimens that are not as well tolerated are likely
to compound any adherence issue. Just as starting ART is
never an emergency, so changing ART is never an emergency.
Changing ART before adherence issues have been resolved is
futile. If it is going to take a while before the adherence issues
are resolved and one is concerned about accumulating new
resistance mutations, there may be justification for stopping
all ART until the family is ready to start the new regimen (see
‘Structured treatment interruptions' below).
Exclude inadequate drug exposure
Another cause of treatment failure is inadequate drug
exposure due to a number of possible factors:
■ Drug not being ingested, e.g. poor adherence, vomiting,
spitting out of a drug such as ritonavir, which is very
unpalatable.
■ Poor absorption. Children with chronic diarrhoea or
malabsorptive states may not be absorbing their ARV
drugs adequately.
■ Increased drug metabolism. Children beyond the
neonatal age have markedly increased drug metabolism
compared with adults. Post-marketing research often
reveals package insert dosages to be inadequate. Consult
updated paediatric ART guidelines for correct dosages.
■ Drug interactions. It is imperative to investigate all
medications the patient is taking (including over-the-
counter drugs and 'herbal' products) for the possibility of
drug interactions with ARV agents. Commonly implicated
drugs include rifampicin, anti-epileptic agents, the non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and St
John’s wort.
FACTORS TO CONSIDER WHEN CHANGING
ANTIRETROVIRAL THERAPY 
Expert advice
As mentioned above, there is no substitute for expert advice
when changing ART. It is a field full of pitfalls for the unwary.
Many patients' futures have been compromised by poor
choices made when changing therapy. Since there is no
emergency in changing ART, there is certainly enough time to
consult with an expert.
Resistance testing
Only genotypic assays are available in South Africa. Adult data
reveal a short-term benefit of resistance testing in terms of
virological response.14,15 Paediatric data are conflicting16-18 and
adequate trials are not available, but most experts would see
themselves as having a role in changing ART in the face of
resistance. Overseas guidelines seem to be recommending
resistance testing with every change of ART regimen due to
treatment failure.10,19 However, its prohibitive cost (over
R3 000) will probably mean that genotyping will only be used
after failure of a second regimen in South Africa. Apart from
the cost, genotyping has other limitations:
■ Genotyping will only give information about the patient’s
current regimen, i.e. it will not give information about viral
resistance to a previous regimen. Therefore a genotyping
Virological considerations
• < 10  (1 log10) decrease from baseline VL at 8 - 12 weeks 
• HIV RNA not undetectable at 4 - 6 months (where initial VLs
are high, an immediate change in therapy may not be
warranted if there is a sustained 1.5 - 2.0 log10 decrease in
HIV RNA copy number, even if RNA remains detectable at
low levels)
• Repeated detection of HIV RNA where previously
undetectable
• Reproducible increase in VL where previously a good
response but low HIV RNA levels: 
< 2 yrs - > 5  (0.7 log10) increase
> 2 yrs - > 3  (0.5 log10) increase
Immunological considerations
• Change in immunological classification (e.g. 2 to 3)
• For children with CD4+ T-cell percentages of < 15% (i.e.
those in immune category 3), a persistent decline of 
5 percentiles or more in CD4+ T-cell percentage (i.e. from
15% to 10%)
• Rapid and substantial decrease in absolute CD4+ T-cell
count (i.e. > 30% decline in < 6 months)
Clinical considerations
• Progressive neuro-developmental deterioration
• Growth failure
• Disease progression, e.g. from clinical category A to B
Adapted from reference 10.
VL = viral load.
TABLE I. CONSIDERATIONS FOR CHANGING THERAPY IN
PAEDIATRIC PATIENTS ON ANTIRETROVIRAL THERAPY
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report suggesting that a virus is sensitive to a certain drug
may not be correct if the patient has previously failed this
drug or a drug in the same class in a previous regimen.
■ Genotyping should be done while the patient is still taking
his/her 'failing' regimen or within 4 weeks of stopping it.19
■ Genotyping needs expert interpretation. It cannot simply
be interpreted as one would a microbiology culture and
sensitivity report, but needs an in-depth analysis by
someone highly experienced in the field who also has all
the details of the patient's previous treatment history. 
At least 2 new drugs
Always try to include at least 2 (preferably 3) new agents.19 The
issue of cross-resistance needs to be borne in mind.
Genotyping may help in selecting which drugs in the present
regimen could be used again. As mentioned, this does not
apply to drugs in a previous regimen, as resistance mutations
to previously taken drugs may not be detected by genotyping.
Preferably a new drug class
Studies have shown that the success of a subsequent regimen
is increased if it contains an ARV drug class to which the
patient has not previously been exposed.20,21 For this reason it
is not a good idea to start with a regimen containing all three
drug classes, as this will mean that there is no new drug class
available for the next regimen. Enfuvirtide is the first of a new
class of drugs, the HIV entry-inhibitors, which is now available
overseas. It is useful in that it allows one to use a new class of
ARV drugs in highly drug-experienced patients. However, its
prohibitive cost and the fact that it must be given by
subcutaneous injection twice daily means that it will probably
have restricted use in South Africa. 
Don't add one drug to a failing regimen
Adding one drug to a failing regimen is likely to result in rapid
development of resistance. It is the equivalent of
monotherapy, which should generally be avoided at all costs. 
Consider cross-resistance
Cross-resistance can be defined as phenotypic resistance to
one drug resulting from mutations (genotypic) selected by
another drug.22 There is no cross-resistance between the
different classes of ARVs. For the nucleoside reverse
transcriptase inhibitor (NRTI) class there may be cross-
resistance, e.g. zidovudine (ZDV) and stavudine (d4T) select for
the same resistance mutations and there is cross-resistance
between them. Generally, however, there is unlikely to be
much NRTI cross-resistance after failing a first regimen.22 With
the NNRTIs, on the other hand, there is a high level of cross-
resistance. Generally it can be assumed that if a patient has
failed any of the NNRTIs, there will be high-level resistance to
the other NNRTIs. Cross-resistance in the protease inhibitor
(PI) class depends on the PI concerned. Some PIs, e.g.
atazanavir, amprenavir and nelfinavir, develop specific primary
mutations first which do not confer cross-resistance to other
PIs. Only after prolonged treatment with a failing PI will
secondary mutations occur that confer cross-resistance to
other PIs. 
Genotyping may help to clarify whether cross-resistance may
be present or not. The help of an expert can be invaluable in
this situation.
Consider drugs used for PMTCT
Numerous studies have confirmed that resistance to
nevirapine (NVP) can occur where mothers and their babies
each receive one dose of NVP for prevention of mother-to-
child transmission (PMTCT). There are emerging data in adults
suggesting reduced efficacy of future NNRTI-containing
regimens.23 It is therefore advisable to avoid NVP and efavirenz
as part of first-line therapy in this situation. Consult the SA
HIV Clinicians Paediatric ART Guidelines on p. 18 of this issue,
where other ARV drugs have been used for MTCT prophylaxis. 
Consider adding 3TC where M184V mutation present to
maintain M184V mutation
Resistant HIV-1 virus with the hallmark lamivudine (3TC)
resistance mutation, M184V, has reduced viral fitness, i.e. it
replicates at a reduced rate and may also reverse resistance to
ZDV, d4T and tenofovir (TDF). For this reason, there may be
value in adding 3TC in a salvage situation even though there
is documented resistance to it. The data, however, are
conflicting.24,25
An example would be a patient who was on 3TC in the first
regimen and developed resistance to it. He subsequently fails
his second regimen. For his third regimen, it is to be hoped
that adding in 3TC as a 4th drug in addition to the 3 new
active drugs will maintain the weaker 3TC-resistant virus,
which will replicate more slowly and be easier to control than
wild-type virus. It has been shown that 3TC monotherapy in
patients who have failed multiple drugs results in slower
disease progression than no therapy at all.26
Pharmacokinetic enhancement
Where a single PI has been used previously there may be a
place for using a 'boosted PI', i.e. adding a small dose of
ritonavir to the PI to inhibit the CYP3A4 enzyme that
metabolises the PI. This results in much higher levels of the PI
and may overcome minor degrees of PI resistance.
Therapeutic drug monitoring (TDM)
TDM is still largely experimental in ART. However, there may be
a place for TDM in salvage therapy with multiple drugs and
multiple possible interactions. Contact the SA HIV Clinicians
Society.
Structured treatment interruptions (STIs)
This approach should only be used on the advice of an expert.
There are three situations in which one might consider
stopping therapy:
■ Infants. Since paediatric HIV infection takes place in the
setting of an immature immune system, treating with
ARVs may allow the immune system to mature. A baby
who has had several months of ART may cope without ART
for several years because the immune system is now
mature enough to produce viral suppression. A study is
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currently underway in South Africa to study this
phenomenon. Until the results are published, this practice
is not recommended. 
■ Infants and children with immune reconstitution. This
is a situation in which the patient’s CD4 count has
recovered but he or she is now failing the current regimen
virologically. Here there may be a place for taking the child
off all therapy and watching the CD4 count carefully. Once
the CD4 count drops below the threshold for starting ART,
a new regimen can be started. Some patients may be able
to go for several years without needing ART, by which time
more effective or safe agents may have become available. 
■ Multidrug-experienced children. Adult data reveal that
there is no place for STIs in a salvage situation.27-29 The
CD4 count drops rapidly and patients are at risk of
developing an opportunistic infection. The only possible
reason to stop treatment in this situation is in order to
resolve an adherence problem.
Mega- or giga-HAART
There are some adult data on the efficacy of empiric multidrug
regimens,30,31 but these are complex and poorly tolerated and
often have unfavourable drug interactions. A feeding
gastrostomy tube may be used to simplify the administration
of so many medications.32
Quality of life in end-stage disease
In patients who have used up all possible options and who are
failing or are unable to tolerate a mega-HAART regimen, there
may be a place for reducing the number of drugs the patient
is taking in order to make life more tolerable. Frequently
patients taking mega-HAART do not tolerate it. A feeding
gastrostomy tube may simplify taking all those medications,32
but if this does not help, or if the patient really cannot tolerate
the drugs, there may be a role for simplifying the regimen.
Even if a regimen is failing, it will delay disease progression
compared with no drugs. It is therefore inadvisable to stop the
ART completely in this situation. Rather, with the help of an
expert, reduce the number of agents to a more tolerable
regimen. As mentioned above, 3TC should always be included
in such a regimen.
New antiretroviral drugs
New agents are being developed, or may already have been
launched overseas, that will be active against resistant virus.
Drugs such as TDF and tipranavir may be useful in the highly
ART-experienced patient. It is always useful to find out from
an expert if there are any new drugs available that could
potentially help a patient. Even if they have not been
registered in this country yet, they may be accessible through
a ‘Section 21’ authorisation from the Medicines Control
Council.
CONCLUSION
Changing ART is a highly complex field, which can have a
major impact on a child's future if not done correctly. For this
reason it is strongly recommended that an expert is consulted
before changing any child's ART. This article is intended to
show the complexity of the subject and the issues that need to
be taken into account, and not as a guide to doing it yourself.
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